{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:08:28Z","timestamp":1790791708551,"version":"4.1.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"vor","delay-in-days":26,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["62172213"],"award-info":[{"award-number":["62172213"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"crossref","award":["2024J08164"],"award-info":[{"award-number":["2024J08164"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Fujian Provincial Health and Wellness Science and Technology Plan Project","award":["2024GGA037"],"award-info":[{"award-number":["2024GGA037"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Epigenet"],"DOI":"10.1186\/s13148-026-02058-4","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T03:53:37Z","timestamp":1769745217000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Characterization and clinical implications of CpG island methylator phenotypes of resistant tumors"],"prefix":"10.1186","volume":"18","author":[{"given":"Fei","family":"Hou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-e","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haizhou","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengqin","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,30]]},"reference":[{"key":"2058_CR1","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.semcancer.2020.12.022","volume":"83","author":"L Guo","year":"2022","unstructured":"Guo L, Lee YT, Zhou Y, Huang Y. Targeting epigenetic regulatory machinery to overcome cancer therapy resistance. Semin Cancer Biol. 2022;83:487\u2013502.","journal-title":"Semin Cancer Biol"},{"issue":"10","key":"2058_CR2","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1038\/nrc3599","volume":"13","author":"C Holohan","year":"2013","unstructured":"Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer. 2013;13(10):714\u201326.","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"2058_CR3","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.ccell.2018.03.025","volume":"33","author":"DJ Konieczkowski","year":"2018","unstructured":"Konieczkowski DJ, Johannessen CM, Garraway LA. A convergence-based framework for cancer drug resistance. Cancer Cell. 2018;33(5):801\u201315.","journal-title":"Cancer Cell"},{"issue":"2","key":"2058_CR4","doi-asserted-by":"publisher","first-page":"bbad066","DOI":"10.1093\/bib\/bbad066","volume":"24","author":"YE Huang","year":"2023","unstructured":"Huang YE, Zhou S, Liu H, Zhou X, et al. Drdriver: identifying drug resistance driver genes using individual-specific gene regulatory network. Brief Bioinform. 2023;24(2):bbad066.","journal-title":"Brief Bioinform"},{"issue":"5","key":"2058_CR5","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.ccr.2010.03.017","volume":"17","author":"H Noushmehr","year":"2010","unstructured":"Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell. 2010;17(5):510\u201322.","journal-title":"Cancer Cell"},{"issue":"9","key":"2058_CR6","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1016\/j.ccell.2023.07.013","volume":"41","author":"WW Liang","year":"2023","unstructured":"Liang WW, Lu RJ, Jayasinghe RG, Foltz SM, et al. Integrative multi-omic cancer profiling reveals DNA methylation patterns associated with therapeutic vulnerability and cell-of-origin. Cancer Cell. 2023;41(9):1567\u201385.","journal-title":"Cancer Cell"},{"issue":"12","key":"2058_CR7","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1038\/nrc1507","volume":"4","author":"JP Issa","year":"2004","unstructured":"Issa JP. CpG island methylator phenotype in cancer. Nat Rev Cancer. 2004;4(12):988\u201393.","journal-title":"Nat Rev Cancer"},{"issue":"7390","key":"2058_CR8","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/nature10866","volume":"483","author":"S Turcan","year":"2012","unstructured":"Turcan S, Rohle D, Goenka A, Walsh LA, et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature. 2012;483(7390):479\u201383.","journal-title":"Nature"},{"issue":"75","key":"2058_CR9","doi-asserted-by":"publisher","first-page":"75ra25","DOI":"10.1126\/scitranslmed.3001875","volume":"3","author":"F Fang","year":"2011","unstructured":"Fang F, Turcan S, Rimner A, Kaufman A, et al. Breast cancer methylomes establish an epigenomic foundation for metastasis. Sci Transl Med. 2011;3(75):75ra25.","journal-title":"Sci Transl Med"},{"issue":"3","key":"2058_CR10","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.cell.2015.12.028","volume":"164","author":"M Ceccarelli","year":"2016","unstructured":"Ceccarelli M, Barthel FP, Malta TM, Sabedot TS, et al. Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma. Cell. 2016;164(3):550\u201363.","journal-title":"Cell"},{"issue":"8","key":"2058_CR11","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.tips.2014.05.004","volume":"35","author":"M Ivanov","year":"2014","unstructured":"Ivanov M, Barragan I, Ingelman-Sundberg M. Epigenetic mechanisms of importance for drug treatment. Trends Pharmacol Sci. 2014;35(8):384\u201396.","journal-title":"Trends Pharmacol Sci"},{"issue":"11","key":"2058_CR12","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.4161\/epi.22561","volume":"7","author":"OA Stefansson","year":"2012","unstructured":"Stefansson OA, Villanueva A, Vidal A, Marti L, et al. BRCA1 epigenetic inactivation predicts sensitivity to platinum-based chemotherapy in breast and ovarian cancer. Epigenetics. 2012;7(11):1225\u20139.","journal-title":"Epigenetics"},{"issue":"4","key":"2058_CR13","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.3892\/ijo.2017.3900","volume":"50","author":"EY Gil","year":"2017","unstructured":"Gil EY, Jo UH, Jeong H, Whang YM, et al. [Corrigendum] Promoter methylation of RASSF1A modulates the effect of the microtubule-targeting agent docetaxel in breast cancer. Int J Oncol. 2017;50(4):1455.","journal-title":"Int J Oncol"},{"issue":"6","key":"2058_CR14","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/bioinformatics\/17.6.520","volume":"17","author":"T Hastie","year":"2001","unstructured":"Hastie T, Tibshirani R, Narasimhan B, Chu G. Impute: Imputation for microarray data. Bioinformatics. 2001;17(6):520\u20135.","journal-title":"Bioinformatics"},{"issue":"12","key":"2058_CR15","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1093\/bioinformatics\/btq170","volume":"26","author":"MD Wilkerson","year":"2010","unstructured":"Wilkerson MD, Hayes DN. Consensusclusterplus: a class discovery tool with confidence assessments and item tracking. Bioinformatics. 2010;26(12):1572\u20133.","journal-title":"Bioinformatics"},{"issue":"1","key":"2058_CR16","doi-asserted-by":"publisher","first-page":"170112","DOI":"10.1038\/sdata.2017.112","volume":"4","author":"S Noguchi","year":"2017","unstructured":"Noguchi S, Arakawa T, Fukuda S, Furuno M, et al. FANTOM5 CAGE profiles of human and mouse samples. Sci Data. 2017;4(1):170112.","journal-title":"Sci Data"},{"issue":"11","key":"2058_CR17","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1101\/gr.239244.118","volume":"28","author":"A Mayakonda","year":"2018","unstructured":"Mayakonda A, Lin DC, Assenov Y, Plass C, et al. Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 2018;28(11):1747\u201356.","journal-title":"Genome Res"},{"issue":"4","key":"2058_CR18","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.immuni.2018.03.023","volume":"48","author":"V Thorsson","year":"2018","unstructured":"Thorsson V, Gibbs DL, Brown SD, Wolf D, et al. The immune landscape of cancer. Immunity. 2018;48(4):812\u201330.","journal-title":"Immunity"},{"issue":"1","key":"2058_CR19","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","volume":"26","author":"MD Robinson","year":"2010","unstructured":"Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;26(1):139\u201340.","journal-title":"Bioinformatics"},{"issue":"6","key":"2058_CR20","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon A, Birger C, Thorvaldsdottir H, Ghandi M, et al. The molecular signatures database (MSigDB) hallmark gene set collection. Cell Syst. 2015;1(6):417\u201325.","journal-title":"Cell Syst"},{"key":"2058_CR21","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1471-2105-14-7","volume":"14","author":"S Hanzelmann","year":"2013","unstructured":"Hanzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinform. 2013;14:7.","journal-title":"BMC Bioinform"},{"key":"2058_CR22","doi-asserted-by":"publisher","first-page":"34000","DOI":"10.1038\/srep34000","volume":"6","author":"C Liu","year":"2016","unstructured":"Liu C, Rohart F, Simpson PT, Khanna KK, et al. Integrating multi-omics data to dissect mechanisms of DNA repair dysregulation in breast cancer. Sci Rep. 2016;6:34000.","journal-title":"Sci Rep"},{"issue":"9","key":"2058_CR23","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1093\/jnci\/djs177","volume":"104","author":"J Kang","year":"2012","unstructured":"Kang J, D\u2019Andrea AD, Kozono D. A DNA repair pathway-focused score for prediction of outcomes in ovarian cancer treated with platinum-based chemotherapy. J Natl Cancer Inst. 2012;104(9):670\u201381.","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"2058_CR24","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/nar\/28.1.27","volume":"28","author":"M Kanehisa","year":"2000","unstructured":"Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000;28(1):27\u201330.","journal-title":"Nucleic Acids Res"},{"issue":"1\u20132","key":"2058_CR25","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.cell.2014.12.033","volume":"160","author":"MS Rooney","year":"2015","unstructured":"Rooney MS, Shukla SA, Wu CJ, Getz G, et al. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell. 2015;160(1\u20132):48\u201361.","journal-title":"Cell"},{"issue":"1","key":"2058_CR26","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1038\/s41467-017-01460-0","volume":"8","author":"M Lauss","year":"2017","unstructured":"Lauss M, Donia M, Harbst K, Andersen R, et al. Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma. Nat Commun. 2017;8(1):1738.","journal-title":"Nat Commun"},{"issue":"11","key":"2058_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v036.i11","volume":"36","author":"MB Kursa","year":"2010","unstructured":"Kursa MB, Rudnicki WR. Feature selection with the Boruta package. J Stat Softw. 2010;36(11):1\u201313.","journal-title":"J Stat Softw"},{"issue":"3","key":"2058_CR28","first-page":"18","volume":"2","author":"A Liaw","year":"2002","unstructured":"Liaw A, Wiener M. Classification and regression by randomForest. R news. 2002;2(3):18\u201322.","journal-title":"R news"},{"issue":"4","key":"2058_CR29","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s00401-018-1810-6","volume":"135","author":"P Bady","year":"2018","unstructured":"Bady P, Kurscheid S, Delorenzi M, Gorlia T, et al. The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033. Acta Neuropathol. 2018;135(4):601\u201315.","journal-title":"Acta Neuropathol"},{"issue":"20","key":"2058_CR30","doi-asserted-by":"publisher","first-page":"4565","DOI":"10.1158\/1078-0432.CCR-22-1133","volume":"28","author":"MJ Mair","year":"2022","unstructured":"Mair MJ, Leibetseder A, Heller G, Puhr R, et al. Early postoperative treatment versus initial observation in CNS WHO grade 2 and 3 oligodendroglioma: clinical outcomes and DNA methylation patterns. Clin Cancer Res. 2022;28(20):4565\u201373.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2058_CR31","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/omi.2011.0118","volume":"16","author":"G Yu","year":"2012","unstructured":"Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16(5):284\u20137.","journal-title":"OMICS"},{"key":"2058_CR32","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbab260","author":"D Maeser","year":"2021","unstructured":"Maeser D, Gruener RF, Huang RS. Oncopredict: an R package for predicting in vivo or cancer patient drug response and biomarkers from cell line screening data. Brief Bioinform. 2021. https:\/\/doi.org\/10.1093\/bib\/bbab260.","journal-title":"Brief Bioinform"},{"key":"2058_CR33","doi-asserted-by":"publisher","first-page":"11459","DOI":"10.1038\/srep11459","volume":"5","author":"M Zhao","year":"2015","unstructured":"Zhao M, Kong L, Liu Y, Qu H. dbEMT: an epithelial-mesenchymal transition associated gene resource. Sci Rep. 2015;5:11459.","journal-title":"Sci Rep"},{"issue":"D1","key":"2058_CR34","doi-asserted-by":"publisher","first-page":"D1210","DOI":"10.1093\/nar\/gkad986","volume":"52","author":"Z Sondka","year":"2024","unstructured":"Sondka Z, Dhir NB, Carvalho-Silva D, Jupe S, et al. COSMIC: a curated database of somatic variants and clinical data for cancer. Nucleic Acids Res. 2024;52(D1):D1210\u20137.","journal-title":"Nucleic Acids Res"},{"key":"2058_CR35","doi-asserted-by":"publisher","first-page":"786728","DOI":"10.3389\/fcell.2021.786728","volume":"9","author":"M Zhang","year":"2021","unstructured":"Zhang M, Zhang YY, Chen Y, Wang J, et al. TGF-beta signaling and resistance to cancer therapy. Front Cell Dev Biol. 2021;9:786728.","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"2058_CR36","doi-asserted-by":"publisher","first-page":"90","DOI":"10.20892\/j.issn.2095-3941.2016.0086","volume":"14","author":"YL Zhang","year":"2017","unstructured":"Zhang YL, Wang RC, Cheng K, Ring BZ, et al. Roles of Rap1 signaling in tumor cell migration and invasion. Cancer Biol Med. 2017;14(1):90\u20139.","journal-title":"Cancer Biol Med"},{"key":"2058_CR37","doi-asserted-by":"publisher","DOI":"10.3390\/cells11132020","author":"MB Ahmed","year":"2022","unstructured":"Ahmed MB, Alghamdi AAA, Islam SU, Lee JS, et al. CAMP signaling in cancer: a PKA-CREB and EPAC-centric approach. Cells. 2022. https:\/\/doi.org\/10.3390\/cells11132020.","journal-title":"Cells"},{"issue":"22","key":"2058_CR38","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1038\/sj.onc.1210421","volume":"26","author":"AS Dhillon","year":"2007","unstructured":"Dhillon AS, Hagan S, Rath O, Kolch W. Map kinase signalling pathways in cancer. Oncogene. 2007;26(22):3279\u201390.","journal-title":"Oncogene"},{"issue":"156","key":"2058_CR39","doi-asserted-by":"publisher","first-page":"156ra140","DOI":"10.1126\/scitranslmed.3004504","volume":"4","author":"H Zouridis","year":"2012","unstructured":"Zouridis H, Deng N, Ivanova T, Zhu Y, et al. Methylation subtypes and large-scale epigenetic alterations in gastric cancer. Sci Transl Med. 2012;4(156):156ra140.","journal-title":"Sci Transl Med"},{"issue":"7","key":"2058_CR40","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1080\/14728222.2018.1487953","volume":"22","author":"S Haase","year":"2018","unstructured":"Haase S, Garcia-Fabiani MB, Carney S, Altshuler D, et al. Mutant ATRX: uncovering a new therapeutic target for glioma. Expert Opin Ther Targets. 2018;22(7):599\u2013613.","journal-title":"Expert Opin Ther Targets"},{"issue":"6","key":"2058_CR41","first-page":"2189","volume":"54","author":"IM Forte","year":"2019","unstructured":"Forte IM, Indovina P, Iannuzzi CA, Cirillo D, et al. Targeted therapy based on p53 reactivation reduces both glioblastoma cell growth and resistance to temozolomide. Int J Oncol. 2019;54(6):2189\u201399.","journal-title":"Int J Oncol"},{"issue":"1","key":"2058_CR42","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.ccr.2009.12.020","volume":"17","author":"RG Verhaak","year":"2010","unstructured":"Verhaak RG, Hoadley KA, Purdom E, Wang V, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17(1):98\u2013110.","journal-title":"Cancer Cell"},{"issue":"2","key":"2058_CR43","doi-asserted-by":"publisher","first-page":"110216","DOI":"10.1016\/j.celrep.2021.110216","volume":"38","author":"T Qin","year":"2022","unstructured":"Qin T, Mullan B, Ravindran R, Messinger D, et al. ATRX loss in glioma results in dysregulation of cell-cycle phase transition and ATM inhibitor radio-sensitization. Cell Rep. 2022;38(2):110216.","journal-title":"Cell Rep"},{"issue":"6","key":"2058_CR44","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1038\/s41379-018-0192-6","volume":"32","author":"G Tachon","year":"2019","unstructured":"Tachon G, Masliantsev K, Rivet P, Petropoulos C, et al. Prognostic significance of MEOX2 in gliomas. Mod Pathol. 2019;32(6):774\u201386.","journal-title":"Mod Pathol"},{"issue":"12","key":"2058_CR45","doi-asserted-by":"publisher","first-page":"e114104","DOI":"10.1371\/journal.pone.0114104","volume":"9","author":"F Avila-Moreno","year":"2014","unstructured":"Avila-Moreno F, Armas-Lopez L, Alvarez-Moran AM, Lopez-Bujanda Z, et al. Overexpression of MEOX2 and TWIST1 is associated with H3K27me3 levels and determines lung cancer chemoresistance and prognosis. PLoS ONE. 2014;9(12):e114104.","journal-title":"PLoS ONE"},{"key":"2058_CR46","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.bbrc.2023.06.089","volume":"674","author":"Y Yoon","year":"2023","unstructured":"Yoon Y, Yoo CR, Kim EC, Han J, et al. STAC1 is required for glioblastoma cell invasion and survival. Biochem Biophys Res Commun. 2023;674:75\u201382.","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"2058_CR47","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1186\/s12885-021-08078-y","volume":"21","author":"RG Manzano","year":"2021","unstructured":"Manzano RG, Catalan-Latorre A, Brugarolas A. RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer. BMC Cancer. 2021;21(1):432.","journal-title":"BMC Cancer"},{"issue":"39","key":"2058_CR48","doi-asserted-by":"publisher","first-page":"6527","DOI":"10.3748\/wjg.v27.i39.6527","volume":"27","author":"A Jain","year":"2021","unstructured":"Jain A, Bhardwaj V. Therapeutic resistance in pancreatic ductal adenocarcinoma: current challenges and future opportunities. World J Gastroenterol. 2021;27(39):6527\u201350.","journal-title":"World J Gastroenterol"},{"issue":"1","key":"2058_CR49","first-page":"125","volume":"41","author":"PF Xu","year":"2019","unstructured":"Xu PF, Yang JA, Liu JH, Yang X, et al. PI3Kbeta inhibitor AZD6482 exerts antiproliferative activity and induces apoptosis in human glioblastoma cells. Oncol Rep. 2019;41(1):125\u201332.","journal-title":"Oncol Rep"},{"issue":"4","key":"2058_CR50","doi-asserted-by":"publisher","first-page":"5274","DOI":"10.18632\/oncotarget.23684","volume":"9","author":"N Awasthi","year":"2018","unstructured":"Awasthi N, Monahan S, Stefaniak A, Schwarz MA, et al. Inhibition of the MEK\/ERK pathway augments nab-paclitaxel-based chemotherapy effects in preclinical models of pancreatic cancer. Oncotarget. 2018;9(4):5274\u201386.","journal-title":"Oncotarget"},{"issue":"11","key":"2058_CR51","first-page":"3747","volume":"31","author":"RA Fryer","year":"2011","unstructured":"Fryer RA, Barlett B, Galustian C, Dalgleish AG. Mechanisms underlying gemcitabine resistance in pancreatic cancer and sensitisation by the iMiD lenalidomide. Anticancer Res. 2011;31(11):3747\u201356.","journal-title":"Anticancer Res"},{"issue":"1","key":"2058_CR52","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s40659-016-0091-6","volume":"49","author":"C Metz","year":"2016","unstructured":"Metz C, Doger R, Riquelme E, Cortes P, et al. Galectin-8 promotes migration and proliferation and prevents apoptosis in U87 glioblastoma cells. Biol Res. 2016;49(1):33.","journal-title":"Biol Res"},{"issue":"1","key":"2058_CR53","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s12967-017-1266-9","volume":"15","author":"R Xu","year":"2017","unstructured":"Xu R, Han M, Xu Y, Zhang X, et al. Coiled-coil domain containing 109B is a HIF1alpha-regulated gene critical for progression of human gliomas. J Transl Med. 2017;15(1):165.","journal-title":"J Transl Med"},{"issue":"5","key":"2058_CR54","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.3892\/ijo.2015.3159","volume":"47","author":"H Brennenstuhl","year":"2015","unstructured":"Brennenstuhl H, Armento A, Braczysnki AK, Mittelbronn M, et al. IkappaBzeta, an atypical member of the inhibitor of nuclear factor kappa B family, is induced by gamma-irradiation in glioma cells, regulating cytokine secretion and associated with poor prognosis. Int J Oncol. 2015;47(5):1971\u201380.","journal-title":"Int J Oncol"},{"issue":"12","key":"2058_CR55","doi-asserted-by":"publisher","first-page":"3425","DOI":"10.1002\/ijc.32587","volume":"145","author":"D Mathios","year":"2019","unstructured":"Mathios D, Hwang T, Xia Y, Phallen J, et al. Genome-wide investigation of intragenic DNA methylation identifies ZMIZ1 gene as a prognostic marker in glioblastoma and multiple cancer types. Int J Cancer. 2019;145(12):3425\u201335.","journal-title":"Int J Cancer"},{"issue":"3","key":"2058_CR56","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1038\/s41591-019-0349-y","volume":"25","author":"J Zhao","year":"2019","unstructured":"Zhao J, Chen AX, Gartrell RD, Silverman AM, et al. Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma. Nat Med. 2019;25(3):462\u20139.","journal-title":"Nat Med"},{"issue":"7","key":"2058_CR57","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1001\/jamaoncol.2020.1024","volume":"6","author":"DA Reardon","year":"2020","unstructured":"Reardon DA, Brandes AA, Omuro A, Mulholland P, et al. Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the CheckMate 143 phase 3 randomized clinical trial. JAMA Oncol. 2020;6(7):1003\u201310.","journal-title":"JAMA Oncol"},{"issue":"1","key":"2058_CR58","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1093\/neuonc\/noac099","volume":"25","author":"A Omuro","year":"2023","unstructured":"Omuro A, Brandes AA, Carpentier AF, Idbaih A, et al. Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: an international randomized phase III trial. Neuro Oncol. 2023;25(1):123\u201334.","journal-title":"Neuro Oncol"},{"issue":"11","key":"2058_CR59","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1093\/neuonc\/noac116","volume":"24","author":"M Lim","year":"2022","unstructured":"Lim M, Weller M, Idbaih A, Steinbach J, et al. Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter. Neuro Oncol. 2022;24(11):1935\u201349.","journal-title":"Neuro Oncol"},{"issue":"2","key":"2058_CR60","doi-asserted-by":"publisher","first-page":"e163447","DOI":"10.1172\/JCI163447","volume":"133","author":"VA Arrieta","year":"2023","unstructured":"Arrieta VA, Dmello C, McGrail DJ, Brat DJ, et al. Immune checkpoint blockade in glioblastoma: from tumor heterogeneity to personalized treatment. J Clin Invest. 2023;133(2):e163447.","journal-title":"J Clin Invest"},{"issue":"7390","key":"2058_CR61","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/nature10860","volume":"483","author":"C Lu","year":"2012","unstructured":"Lu C, Ward PS, Kapoor GS, Rohle D, et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature. 2012;483(7390):474\u20138.","journal-title":"Nature"}],"container-title":["Clinical Epigenetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13148-026-02058-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-026-02058-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-026-02058-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T12:59:04Z","timestamp":1772024344000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13148-026-02058-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,30]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2058"],"URL":"https:\/\/doi.org\/10.1186\/s13148-026-02058-4","relation":{},"ISSN":["1868-7083"],"issn-type":[{"value":"1868-7083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,30]]},"assertion":[{"value":"14 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}],"article-number":"37"}}